Zephyr AI

Where Zephyr AI may be positioned to perform (based on public positioning): - access to oncology cohorts via Aster Insights and ORIEN/Total Cancer Care - emphasis on biologically explainable response predictions (AIM‑Bx) - approaches intended to extract signal from multimodal RWD Where competitors may have comparative advantages: - Flatiron Health: broad adoption for oncology RWE, extensive publication footprint, and established RWE operations. - Tempus: integrated diagnostics and multimodal datasets, with a substantial commercial footprint. - ConcertAI: oncology RWD footprint and AI SaaS modules across trials, imaging, and evidence generation. Public, direct customer head‑to‑head testimonials comparing Zephyr AI to these competitors were not found in accessible sources during this research pass. Sources: Official vendor documentation and product pages; company websites and industry press.